MAOA provides prostate cancer cells with cell growth advantages in the bone microenvironment by stimulating IL-6 release from osteoblasts and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL [67]. The gene discussed is TNFSF11; the disease is Familial prostate cancer.